Total : 3 View more »
SOUTH SAN FRANCISCO, Calif., Oct. 16 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL - News) today announced that it will webcast its analyst briefing on October
http://finance.yahoo.com/news/Rigel-to-Webcast-Analyst-prnews-4275234965.html?x=0&.v=1
SOUTH SAN FRANCISCO, Calif., Oct. 28 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL - News) today announced that James M. Gower, chairman and chief executive officer,
http://finance.yahoo.com/news/Rigel-Announces-Presentations-prnews-4008147458.html?x=0&.v=1
SOUTH SAN FRANCISCO, Calif. (AP) -- Rigel Pharmaceuticals Inc. said Thursday it has priced a public offering of 13 million shares at $7.25 per share.The underwriters
http://finance.yahoo.com/news/Rigel-Pharmaceuticals-prices-apf-3703619742.html?x=0&.v=1
Total : 27 View more »
Nov 23, 2009 (SmarTrend(R) Spotlight via COMTEX) --
Rigel Pharmaceuticals (NASDAQ:RIGL) upgraded to Outperform, $11 target, at RBC Capital. The stock closed Friday at $7.78 on volume of 332,905 shares, below average daily volume of 914,004.
Rigel Pharmaceuticals is currently above its 50-day moving average of $7.35 and should find resistance at its 200-day moving average of $8.06.
SmarTrend is bullish on shares of RIGL and our subscribers received an Uptrend alert on November 09, 2009 at $7.70, which has returned 1% to date.
Write to Chip Brian at cbrian@tradethetrend.com
---------------------------------------------------------------------------------------------
SmarTrend analyzes over 5,000 securities simultaneously throughout the trading day and provides its subscribers with trend change alerts in real time. To get a free trial of our trading calls and maximize your trading results, please visit http://www.TradeTheTrend.com.
Get exclusive, actionable insight into how the market is expected to trend prior to market open with our free morning newsletter. Sign up at: http://www.TradeTheTrend.com/signup.html
Tags: market nasdaq pharmaceuticals securities
Companies: Rigel Pharmaceuticals, Inc. (RIGL)
Nov 06, 2009 (SmarTrend(R) Spotlight via COMTEX) --
SmarTrend, our proprietary pattern recognition system, called a Downtrend for Rigel Pharmaceuticals (NASDAQ:RIGL) on July 24, 2009 at $10.11.
Since then, Rigel Pharmaceuticals has returned 28.8% as of today's recent price of $7.19. Want to profit from these alerts?
Go to www.mysmartrend.com now for a FREE two-week trial.
Write to Chip Brian at cbrian@tradethetrend.com
---------------------------------------------------------------------------------------------
SmarTrend analyzes over 5,000 securities simultaneously throughout the trading day and provides its subscribers with trend change alerts in real time. To get a free trial of our trading calls and maximize your trading results, please visit http://www.TradeTheTrend.com.
Get exclusive, actionable insight into how the market is expected to trend prior to market open with our free morning newsletter. Sign up at: http://www.TradeTheTrend.com/signup.html
Tags: market nasdaq pharmaceuticals profit securities trial
Companies: Rigel Pharmaceuticals, Inc. (RIGL)
HENDERSON, NV, Oct 28, 2009 (M2 PRESSWIRE via COMTEX) --
Monsterstox.com is pleased to offer a hot stock alerts service. Investors can receive FREE Stock Alerts by visiting the following link: http://www.Monsterstox.com
Today's hot alert includes :Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL)
Rigel Announces Presentations at Two Investor Conferences
SOUTH SAN FRANCISCO, Calif., Oct. 28 -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, chairman and chief executive officer, and Raul R. Rodriguez, executive vice president and chief operating officer of Rigel, will present at two separate investor conferences in November.
Monsterstox.com offers daily newsletter on potentially huge movers in the market. These include stocks with momentum and abnormal volume. We also profile undervalued stocks, penny stocks, stocks with positive technical indicators and much more. Our team of experienced Traders search the market for stocks that are overlooked by the crowd.
We encourage investors to join to our FREE newsletter by visiting: http://www.Monsterstox.com
ABOUT MONSTERSTOX.COM
Monsterstox.com is a leading stock website that provides FREE newsletters on stocks that are potential huge movers. Monsterstox.com also tracks micro cap stocks that could be undervalued by the market. Monsterstox.com strives to provide an edge to Traders and Investors with its FREE newsletter service.
Monsterstox.com is an independent electronic publication that provides information on selected publicly traded companies. Monsterstox.com is not a registered investment advisor or broker-dealer. Monsterstox.com affiliates, officers, directors and employees may buy and sell additional shares in any company mentioned herein and may profit in the event those shares rise in value. Please do your own Due Diligence before investing in any of the stocks mentioned above.
CONTACT: Monsterstox.com e-mail: info@monsterstox.com WWW: http://www.Monsterstox.com
((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
Tags: advisor broker california ceo dealer e-mail executive investment investment opinion micro cap nasdaq pharmaceuticals president profit web
Companies: Rigel Pharmaceuticals, Inc. (RIGL)
Oct 26, 2009 (SmarTrend(R) Spotlight via COMTEX) --
Rigel Pharmaceuticals (NASDAQ:RIGL) is trading 1.3% lower (down $0.09 to $6.58) today on volume of 101,884 shares. The stock has traded within a 52-week range of $4.19 and $14.75.
Rigel Pharmaceuticals is currently below its 50-day moving average of $7.53 and below its 200-day moving average of $8.06.
SmarTrend is bearish on shares of RIGL and our subscribers received a Downtrend alert on July 24, 2009 at $10.11, which has returned 34.9% to date.
Write to Chip Brian at cbrian@tradethetrend.com
---------------------------------------------------------------------------------------------
SmarTrend analyzes over 5,000 securities simultaneously throughout the trading day and provides its subscribers with trend change alerts in real time. To get a free trial of our trading calls and maximize your trading results, please visit http://www.TradeTheTrend.com.
Get exclusive, actionable insight into how the market is expected to trend prior to market open with our free morning newsletter. Sign up at: http://www.TradeTheTrend.com/signup.html
Tags: market nasdaq pharmaceuticals securities
Companies: Rigel Pharmaceuticals, Inc. (RIGL)
Total : 6 View more »
Copyright © 2002 - 2008 newratings.com GmbH | Legal | Licensing Quote data provided by IS.eFinance Solutions (powered by IS.Teledata AG) using StandardPoor's ComStock Inc. and others. Delay times are 15 mins for European exchanges and NASDAQ, 20 mins for NYSE and AMEX.
http://www.newratings.com/headlines/Rigel-Pharmaceuticals_US7665591084.html
Stock earnings, recommendations and SEC filings for Rigel Pharmaceuticals, Inc.
EvaluatePharma provides historic and forecast sales from 1986 to 2010 for worldwide and US Rx (prescription drugs) and OTC drugs. EvaluatePharma analysts continuously update company models from SEC filings, annual reports, investor/analyst presentations, company press releases, FDA and USPTO.
Rigel Pharmaceuticals Inc has received two milestone payments from Daiichi Pharmaceuticals Co Ltd (Daiichi) as part of their collaboration to identify a new type of oncology drug.
http://www.pharmacychoice.com/News/article.cfm?Article_ID=3747
Total : 47 View more »
Stay informed on the latest Rigel Pharmaceuticals Incorporated news. TheStreet is the source for financial market and Wall Street news, trading stock and personal finance advice.
http://www.thestreet.com/topic/6063/rigel-pharmaceuticals-incorporated.html
Rigel Pharmaceuticals, Incorporated 7413870 SAK: modulation of cellular proliferation for treatment of cancer
http://www.patents.com/Rigel-Pharmaceuticals-Incorporated/South-San-Francisco/CA/51494/company/
Get the latest RIGL - Rigel Pharmaceuticals Incorporated stock market performance data. TheStreet is the source for financial market news, trading stock, quotes, and personal ...
Jean Deleage, Ph.D., age 68, joined us as a director in January 1997. Dr ... Top Executives at Rigel Pharmaceuticals, Incorporated